Clinical trials: Patients With Bipolar Disorders
Bipolar I Disorder
A Comparison of Olanzapine in Combination With a Mood Stabilizer vs Mood Stabilizer Alone, in Mixed Bipolar Patients
Whether treatment with olanzapine in combination with mood stabilizer reduces symptoms of both mania and depression more than treatment with mood stabilizer alone, in patients with a mixed episode of bipolar I disorder.
- Trial name
- NCT00402324
- Testing
- olanzapine, divalproex
- Where
- United States
- Volunteers
- 202 people
- Sponsor
- Eli Lilly and Company
Antipsychotic-induced Weight Gain (AIWG)
A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications
This phase 2, double blind, placebo-controlled, randomized study is to assess the safety, efficacy, and pharmacokinetics (PK) of miricorilant (CORT118335) in obese adults with schizophrenia or bipolar disorder treated with…
- Trial name
- GRATITUDE (NCT03818256)
- Testing
- Miricorilant
- Where
- 27 sites in United States
- Volunteers
- 71 people
- Sponsor
- Corcept Therapeutics
Second Generation Antipsychotic Induced Metabolic Adverse Effects
Metabolic Effects of Melatonin in Patients Treated With Second Generation Antipsychotics
Schizophrenia and bipolar disorder are frequently associated with an elevated risk for obesity, metabolic syndrome, diabetes mellitus, dyslipidemia and other metabolic disturbances.
- Trial name
- NCT01811160
- Testing
- Melatonin
- Where
- Mexico
- Volunteers
- 50 people
- Sponsor
- Instituto Nacional de Psiquiatría Dr. Ramón de la Fuente
Bipolar Depression
Task-State-Based Temporal Interference Stimulation (TI) to Improve Depression in Patients With Bipolar Disorder
The purpose of this study is to investigate the efficacy and safety of temporal interference stimulation (TI) in improving depressive episodes of bipolar disorder, to analyze the therapeutic principle of TI in bipolar disorder…
- Trial name
- NCT06516991
- Testing
- Temporal Interference Stimulation
- Where
- China
- Volunteers
- 36 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Behavioral Variant of Frontotemporal Disorder (bvFTD), Phenocopy Frontotemporal Dementia (phFTD)
Premorbid Personality Profile of Patients With Cognitive and Behavioral Disorders
Damages in frontal area present in neurodegenerative disease (frontotemporal degeneration, frontal variant of Alzheimer disease) and in psychiatric disease (bipolar disorder) can affect behavior and cognition including social…
- Conditions
- Behavioral Variant of Frontotemporal Disorder (bvFTD), Phenocopy Frontotemporal Dementia (phFTD), Frontal Variant of Alzheimer Disease, Bipolar Disorder
- Trial name
- NCT06059313
- Testing
- Submission of the NEO-PI-3 questionnaire, Submission of the Interpersonal Reactivity Index questionnaire (IRI)
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Nantes University Hospital
Bipolar Disorder
Topiramate Versus Placebo as add-on Treatment in Patients With Bipolar Disorder in the Outpatient Setting
The purpose of this study is to assess the efficacy and safety of adding topiramate as compared to placebo to the medications a patient with bipolar disorder is already taking (lithium or valproate) to see if adding topiramate…
- Trial name
- NCT00237289
- Testing
- topiramate
- Volunteers
- 287 people
- Sponsor
- Ortho-McNeil Neurologics, Inc.
Severe Mental Disorder, Smoking Cessation
Tobacco Intensive Motivational and Estimate Risk
Randomized, open label, prospective study with a 12-month follow-up period. The primary objective evaluates the effectiveness of an intensive anti-smoking programme that informs patients of their individual risk of lung damages…
- Conditions
- Severe Mental Disorder, Smoking Cessation, COPD
- Trial name
- NCT03583203
- Testing
- personalized information about lung damage
- Where
- Spain
- Volunteers
- 230 people
- Sponsor
- Hospital Universitario Reina Sofia de Cordoba
Bipolar Disorder, Major Depression
Effectiveness of mHealth Post-discharge Intervention for Patients With Severe Mental Illness
The overall aim of this program of research is to improve the continuity of care for patients with serious mental illness (SMI) by supporting a safer and more efficient bridge from hospital to outpatient care using a mobile…
- Conditions
- Bipolar Disorder, Major Depression, Schizophrenia
- Trial name
- tFOCUS (NCT05703412)
- Testing
- Transition-FOCUS mHealth Intervention, Check-In
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Butler Hospital
Schizophrenia, Schizoaffective Disorder
A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
Varenicline (Chantix) is a smoking cessation treatment that was approved in 2006 by the FDA for treatment of nicotine dependence and may be particularly beneficial in smokers with schizophrenia or bipolar disorder.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Smoking
- Trial name
- SCRP (NCT00621777)
- Testing
- Varenicline
- Where
- 10 sites in United States
- Volunteers
- 247 people
- Sponsor
- Massachusetts General Hospital
Depressive Disorder, Depression
The Role of Inflammatory Processes in Development and Treatment of Depression
The study investigates the influence of inflammatory processes on the development and the course of uni- and bipolar depression.
- Conditions
- Depressive Disorder, Depression, Inflammation
- Trial name
- INFLAME-D (NCT03920475)
- Testing
- Sertraline or venlafaxine, Immune parameters
- Volunteers
- 104 people
- Sponsor
- Kliniken Essen-Mitte
Bipolar Disorder
The Study of Effectiveness Repetitive Transcranial Magnetic Stimulation in Bipolar Depression
The aim of this study is to investigate the effect of repetitive TMS in reduction of depressive symptoms in patients with bipolar disorder.
- Trial name
- NCT01932749
- Testing
- Transcranial Magnetic stimulation
- Where
- Iran
- Volunteers
- 30 people
- Sponsor
- University of Tehran
Metastatic Castration-resistant Prostate Cancer
The COSMYC Trial (COmbined Suppression of MYC)
This research is being done to determine if receiving the combination of testosterone and ZEN-3694 followed by the combination of enzalutamide plus ZEN-3694 will decrease the size of tumors in patients with prostate cancer that…
- Trial name
- NCT06922318
- Testing
- ZEN-3694, Testosterone cypionate, Enzalutamide
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Bipolar Disorder
Rostral Dorsal Cingulum Bundle Connectivity in Patients With Bipolar Disorder
The overall goal of this study is to employ diffusion-weighted imaging (DWI) and tractography to investigate differences in connectivity in the rostral dorsal cingulum bundle (CB) in patients with bipolar disorder type I (BDI) or…
- Trial name
- NCT02655978
- Testing
- Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- University Hospitals Cleveland Medical Center
Schizophrenia, Bipolar Disorder
Physician Survey on Monitoring of Patients Treated With Quetiapine
A physician survey to document receipt of metabolic educational materials and assess behavior of physicians in following messages communicated through the educational materials
- Conditions
- Schizophrenia, Bipolar Disorder, Major Depressive Disorder
- Trial name
- NCT01795326
- Volunteers
- 800 people
- Sponsor
- AstraZeneca
Bipolar Disorder
Psychoeducation for Patients With Bipolar Disorder in Rwanda
Background: Mental health- and neurological disorders constitute 13% of the global burden of disease. Alarmingly this burden has risen by 41% in the last 20 years.
- Trial name
- NCT04671225
- Testing
- Groups Psychoeducation, Waiting-list
- Where
- 2 sites in Rwanda
- Volunteers
- 154 people
- Sponsor
- University of Aarhus
Bipolar Disorder, Depression, Bipolar
Safety and Efficacy Trial of the Use of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Patients With Bipolar Depression
The purpose of this study is to evaluate the efficacy and safety of quetiapine in the treatment of a major depressive episode in patients with bipolar disorder.
- Trial name
- NCT00060489
- Testing
- SEROQUEL (quetiapine fumarate) Tablets
- Where
- 27 sites in United States
- Sponsor
- AstraZeneca
Schizophrenic Disorders, Schizoaffective Disorders
Effectiveness of a Physical Activity and Diet Program in Patients With Psychotic Disorder (CapiCor)
The aim is to evaluate the effectiveness of an intervention based on a program of physical activity and diet coordinated between primary care teams (PCT) and Mental Health Centres (MHC) to modify the weekly physical activity (PA)…
- Conditions
- Schizophrenic Disorders, Schizoaffective Disorders, Bipolar Disorders
- Trial name
- CapiCor (NCT01729650)
- Testing
- Physical and diet educational group
- Where
- Spain
- Volunteers
- 332 people
- Sponsor
- Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
Sexual Dysfunction, Hyperprolactinemia
A Multicenter Study to Evaluate the Effects of Switching to Aripiprazole 12 Weeks on the Sexual Dysfunction From Risperidone or Paliperidone in Patients With Schizophrenia Spectrum Disorders or Bipolar Spectrum Disorders
This trial designed to investigate the effect of switching to aripiprazole from risperidone or paliperidone on reverse prolactin level, and consequently improve sexual dysfunction in adult patients with schizophrenia spectrum…
- Trial name
- NCT01742390
- Testing
- Aripiprazole, risperidone or paliperidone
- Where
- 2 sites in China
- Volunteers
- 120 people
- Sponsor
- Si Tianmei
Covid19, Severe Mental Disorder
COVID-19 Serological Testing of Patients With a Mental Disorder From the Catchment Area of the Capital Region of Denmark
The pandemic of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has lately caused worldwide health problems.
- Trial name
- NCT04775407
- Testing
- blood sampling
- Where
- Denmark
- Volunteers
- 1,355 people
- Sponsor
- Anders Fink-Jensen, MD, DMSci
Bipolar I
Open-label Study to Evaluate the Effectiveness of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder
This will be an open-label uncontrolled trial to evaluate the safety and tolerability of aripiprazole IM depot administered every 4 weeks for up to 52 weeks to patients with bipolar I disorder.
- Trial name
- ATLAS (NCT01710709)
- Testing
- Aripiprazole
- Where
- 142 sites in United States, Canada and 8 more
- Volunteers
- 748 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.